A Phase 2/3 interventional study of plecanatide and Placebo in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 121 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-28.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 6th largest by enrollment, is the only one that started in 2011, is the only one in phase 2/3, and was the 2nd registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2011.
This study's enrollment of 951 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2011, is the only one in phase 2/3, and was the 10th registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).
This is a Phase IIb/III, randomized, double-blind, placebo-controlled, 12-Week, Repeat, Oral Dose Ranging, study to determine the safety and efficacy of plecanatide in patients with chronic idiopathic constipation (CIC). Subjects diagnosed with CIC via modified Rome III criteria will be screened against the inclusion and exclusion criteria for the study and enter a 2 Week pre treatment screening. During this phase patients will be required to call in their bowel movements (BM diary) as they occur, and call at least once daily to complete a patient diary of questions on their symptoms (Symptom Diary) associated with CC, as they will throughout the trial. Patients who complete at least 5 days of dosing per week, 6 of each 7 day period of BM diary calls, and continue to have less than 3 complete spontaneous movements per week (as well as meeting other inclusion and exclusion criteria) will be enrolled and randomized to one of three plecanatide doses 0.3 mg, 1.0 mg, and 3.0 mg or placebo. 880 patients will be randomized with the intent of having 200 patients per treatment group (each group the same size) included in efficacy analyses. All subjects receiving at least one dose of plecanatide or matching placebo will be included in the safety analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
Drug: plecanatide
Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
Drug: plecanatide
Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
Drug: plecanatide
Subjects receive placebo for 12 consecutive weeks
Other: Placebo
Subjects receive experimental study drug for 12 weeks.
Also known as: Trulance
Subjects receive experimental study drug for 12 weeks.
Overall Responder 9/12 Weeks
A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation. A weekly responder will have 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week. An overall responder is a patient who is a weekly responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks.
Time frame: 12-Week Treatment Period
Change From Baseline in 12-week CSBM Weekly Frequency Rate
The number of Complete Spontaneous Bowel Movements (CSBMs) per week
Time frame: 12-Week Treatment Period
Change From Baseline in 12-week SBM Weekly Frequency Rate
The number of Spontaneous Bowl Movements experienced per week.
Time frame: 12-Week Treatment Period
Change From Baseline in Stool Consistency (BSFS) to Over Treatment Period
The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)
Time frame: 12-Week Treatment Period
Change From Baseline in 12-week Patient Reported Symptoms Associated With Constipation - Straining Score
The severity of straining (Straining Score) was reported by the patients using a 11-point scale (0-10) where 0 = none and 10 = the worst
Time frame: 12-Week Treatment Period
| Milestone | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| Started | 238 | 238 | 238 | 237 |
| Completed | 189 | 176 | 202 | 171 |
| Not completed | 49 | 62 | 36 | 66 |
A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation. A weekly responder will have 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week. An overall responder is a patient who is a weekly responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks.
| % of Overall Responder 9/12 weeks | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| Overall Responder 9/12 Weeks | 18.6 | 16.8 | 19.0 | 10.7 |
The number of Complete Spontaneous Bowel Movements (CSBMs) per week
| CSBMs per week | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in 12-week CSBM Weekly Frequency Rate | 1.60 ± 0.159 | 1.81 ± 0.157 | 2.18 ± 0.159 | 1.09 ± 0.162 |
The number of Spontaneous Bowl Movements experienced per week.
| SBMs per week | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in 12-week SBM Weekly Frequency Rate | 2.20 ± 0.190 | 2.38 ± 0.188 | 3.00 ± 0.191 | 1.35 ± 0.194 |
The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)
| scores on a scale | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Stool Consistency (BSFS) to Over Treatment Period | 1.28 ± 0.090 | 1.70 ± 0.090 | 1.97 ± 0.089 | 0.87 ± 0.091 |
The severity of straining (Straining Score) was reported by the patients using a 11-point scale (0-10) where 0 = none and 10 = the worst
| scores on a scale | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in 12-week Patient Reported Symptoms Associated With Constipation - Straining Score | -1.25 ± 0.142 | -1.46 ± 0.142 | -1.73 ± 0.143 | -1.04 ± 0.144 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Plecanatide 0.3 mg | — | 1/237 (0.4%) | 55/237 (23.2%) |
| Plecanatide 1.0 mg | — | 1/238 (0.4%) | 79/238 (33.2%) |
| Plecanatide 3.0 mg | — | 2/237 (0.8%) | 92/237 (38.8%) |
| Placebo | — | 5/236 (2.1%) | 45/236 (19.1%) |
| Event | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 1/237 | 0/238 | 0/237 | 1/236 |
| GastroenteritisInfections and infestations | 0/237 | 0/238 | 0/237 | 1/236 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/237 | 0/238 | 0/237 | 1/236 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/237 | 0/238 | 0/237 | 1/236 |
| HypertensionVascular disorders | 0/237 | 0/238 | 0/237 | 1/236 |
| AstheniaGeneral disorders | 0/237 | 0/238 | 1/237 | 0/236 |
| Cholecystitis AcuteHepatobiliary disorders | 0/237 | 0/238 | 1/237 | 0/236 |
| HypoaesthesiaNervous system disorders | 0/237 | 0/238 | 1/237 | 0/236 |
| EndometriosisReproductive system and breast disorders | 0/237 | 1/238 | 0/237 | 0/236 |
| Event | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 13/237 | 20/238 | 23/237 | 3/236 |
| FlatulenceGastrointestinal disorders | 5/237 | 3/238 | 14/237 | 5/236 |
| Abdominal PainGastrointestinal disorders | 6/237 | 9/238 | 12/237 | 11/236 |
| NauseaGastrointestinal disorders | 5/237 | 12/238 | 8/237 | 5/236 |
| HeadacheNervous system disorders | 10/237 | 11/238 | 9/237 | 5/236 |
| Abdominal DistensionGastrointestinal disorders | 5/237 | 10/238 | 9/237 | 5/236 |
| Upper Respiratory tract infectionInfections and infestations | 6/237 | 5/238 | 9/237 | 5/236 |
| Urinary Tract InfectionInfections and infestations | 5/237 | 9/238 | 8/237 | 6/236 |
The mITT population included all randomized patients who received ≥ 1 dose of study drug and ≥ 1 post-baseline BM assessment. 951 patients were randomized; 3 were not treated and 2 received study drug but did not complete a post-dose assessment, yielding 946 patients in the mITT population.
| Age, Continuous(years) | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 47.8 (20 to 75) | 47.1 (18 to 75) | 47.1 (18 to 75) | 46.3 (19 to 75) | 47.1 (18 to 75) |
| Sex: Female, Male(Participants) | Plecanatide 0.3 mg | Plecanatide 1.0 mg | Plecanatide 3.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 203 | 202 | 205 | 207 | 817 |
| Male | 34 | 36 | 32 | 27 | 129 |
Showing the first 100 of 121 sites. Choose a country and city above to see the rest.
The record gives a start of Oct 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2017, 4 years 11 months after primary completion. A results delay was requested in Apr 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →